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Background
There are many critical steps for the clinical efficacy of
antigen-specific T cell-based immunotherapies among
which traffic to and access to tumor beds of effector
T cells, are the most limiting [1]. Preclinical research
most often uses ectopic mouse tumor models for the
readout fastness and easiness provided by such models.
However, those models may not be the optimal way to
address the issue of targeting effector T cells to a deep
organ born tumor.
Methods
We set up an orthotopic preclinical model in which
renal carcinoma cells (RenCa) expressing the human
mucin 1 tumor-associated xeno-antigen are injected into
the sub-capsular space of kidney in BALB/c mice. We
then evaluated the impact of the route of injection on
the therapeutic efficacy of a Modified Vaccinia virus
Ankara expressing the human mucin 1 xeno-antigen
(MVA-MUC1).
Results
We show that intravenous administration of MVA-MUC1
is therapeutically superior to subcutaneous injection.
Therapeutic efficacy of MVA-MUC1 can be further
enhanced by intravenous administration of a TLR9 ligand
(ODN1826). Substantial and necessary infiltration of
tumor-bearing kidneys by CD8+ lymphocytes is associated
with therapeutic protection. We observe that infiltration
of CD8+ lymphocytes is not limited to tumor-bearing kid-
neys and is also detected in naive kidneys, liver and lungs.
Kidney infiltrating lymphocytes are characterized by an
effector memory phenotype and express PD-1 and Tim3
immune checkpoints molecules. Biodistribution experi-
ments indicate that MVA encoded antigens quickly reach
deep organs and in particular APC from the spleen upon
i.v. injection of MVA in comparison to s.c. injection,
resulting in a faster generation of MUC1 specific CD8+
T cells. Unexpectedly, addition of ODN1826 to MVA-
MUC1 immunization does not result in an increase in the
frequency of MUC1 specific T cells detected in the spleen.
Instead, ODN1826 was associated with a more pro-
nounced modification of the tumor microenvironment
towards a TH1 type inflammatory response and a recruit-
ment of activated lymphocytes.
Conclusions
Intravenous injection of MVA-MUC1 is associated with
therapeutic efficacy and deep organ infiltration by
MUC1-specific CD8+ T cells in an orthotopic model of
renal carcinoma. This therapeutic efficacy can be
further increased through the use of ODN1826. This
study supports the clinical evaluation of MVA-based
immunotherapies via the intravenous route.
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